Viking Therapeutics/$VKTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
46
ISIN
US92686J1060
Website
VKTX Metrics
BasicAdvanced
$3B
-
-$1.15
0.83
-
Price and volume
Market cap
$3B
Beta
0.83
52-week high
$74.15
52-week low
$18.92
Average daily volume
3.4M
Financial strength
Current ratio
44.246
Quick ratio
43.522
Long term debt to equity
0.059
Total debt to equity
0.118
Interest coverage (TTM)
-1,914.63%
Profitability
Management effectiveness
Return on assets (TTM)
-11.74%
Return on equity (TTM)
-14.40%
Valuation
Price to book
3.54
Price to tangible book (TTM)
3.54
Price to free cash flow (TTM)
-22.132
Free cash flow yield (TTM)
-4.52%
Free cash flow per share (TTM)
-120.50%
Growth
Earnings per share change (TTM)
23.83%
3-year earnings per share growth (CAGR)
16.19%
10-year earnings per share growth (CAGR)
-15.29%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Bulls say / Bears say
Viking Therapeutics has completed enrollment in its Phase 2 VENTURE trial for VK2735, a dual GLP-1 and GIP receptor agonist for obesity treatment, with results expected in the second half of 2025. (stocktitan.net)
The company reported positive results from its Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy, showing significant reductions in plasma levels of very long-chain fatty acids. (stocktitan.net)
Viking Therapeutics has a strong cash position, with $362 million reported at the end of 2023, providing financial stability for ongoing and future clinical trials. (biospace.com)
The company reported a net loss of $35.4 million for Q4 2024, an increase from the $24.6 million loss in the same period of 2023, indicating rising operational expenses. (marketchameleon.com)
Research and development expenses increased to $31.0 million in Q4 2024 from $20.5 million in Q4 2023, reflecting higher costs associated with advancing clinical programs. (marketchameleon.com)
General and administrative expenses rose to $15.3 million in Q4 2024, up from $8.8 million in Q4 2023, due to increased costs related to legal and patent services, stock-based compensation, and other administrative expenses. (marketchameleon.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $3B as of July 02, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of July 02, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.